c-MRS : custom Meganuclease Recombination System

Custom MRS (or c-MRS) is a product generated by the meganuclease platform and developed into a fully integrated genome engineering system.
c-MRSs are based on the use of a custom meganuclease engineered by Cellectis and a DNA targeting matrix sharing some similarities upstream and downstream the target DNA sequence to be modified. These two compounds (custom meganuclease and DNA targeting matrix) make a c-MRS that can be used in multiple genome engineering applications by our partners.
Cellectis achieves for partners the development of a custom meganuclease specific to a DNA target and delivers an operational reverse genetics product, which is a proprietary c-MRS targeted to modify a pre-identified locus of interest.

Cellectis delivers c-MRS: a locus specific genome reprogramming toolkit box

• An engineered custom meganuclease cleaving with a very high specificity the target DNA, and
• A DNA targeting matrix sharing similarities upstream and downstream the meganuclease cut site within the chromosomal DNA target. The DNA targeting matrix is the compound used to introduce the genetic change within the chromosome.

All our products are provided with the best expertise and assistance in genome engineering and DNA recombination.

c-MRS will allow you to target your preferred chromosomal target for any insertion, deletion, replacement or repair and according to your reverse genetics plans.

Example of the targeted action of a meganuclease for site-directed gene insertion at a specific locus:

Cellectis is the world leader specialized in genome engineering.

The use of MRS and homologous recombination provides Cellectis with unique advantages because:

• Cellectis' technology is natural and efficient: the generation of a site-directed break and the use of the endogenous repair system of the cell ensures simplicity and efficiency.
• The effect of one c-MRS is restricted to targeted loci: c-MRS aims at precise and flexible genome surgery, modifications that are strictly directed to the targeted locus.
• A c-MRS operation is a temporally restricted act with long lasting effects: the action of the c-MRS relies on the transient presence of the custom meganuclease and the DNA targeting matrix (the reprogramming material). Nevertheless, the resulting genome modification is permanent.
• Cellectis' c-MRS technology, can allow a wide variety of genomic interventions such as: removal of deleterious mutations or viruses, metabolic engineering or expression of endogenous or exogenous proteins or DNA sequences in living cells and organisms.
• Cellectis' technology provides unique opportunities in many fields: therapeutic, bio-productions, biological models by putting within the reach of its partners valuable complex genomic changes.
  The possibility to modify any locus at will unplugs creativity in new fields of the post-genomic era.